Category AGIO

Agios is not the same story it was one year ago, and it is not even the same story it was right after the market reacted badly to the November 2025 RISE UP data. The cleanest way to frame the company today is not as a single-product binary biotech and not as a fully de-risked rare-disease compounder either. It sits somewhere in the middle. There is now a real commercial base, a very strong balance sheet by biotech standards, a broader geographic footprint for mitapivat in thalassemia, and a reopened regulatory path in sickle cell disease that most investors had at least partially discounted after the mixed Phase 3 readout.

A year ago, Agios was still mostly a “promise stock”: one approved niche drug for pyruvate kinase deficiency and a lot of hope around sickle cell disease. Today the picture is more complex but also more concrete: mitapivat now has two U.S. approvals, a full rare-disease haematology franchise is forming, and 2026 has a surprisingly busy catalyst map.